Ptc Therapeutics (PTCT) FCF Margin (2012 - 2026)

Ptc Therapeutics' FCF Margin history runs 15 years deep, the most recent figure standing at 35.21% for Q2 2026.

• In Q2 2026, FCF Margin rose 6851.0% year-over-year to 35.21%; the TTM figure through Jun 2026 stood at 3.94% (down 4346.0% YoY), while the FY2025 annual figure was 40.58%, up 5474.0% from the prior year.
• FCF Margin for Q2 2026 stood at 35.21%, up from 22.1% in the prior quarter.
• The five-year high for FCF Margin was 73.84% in Q1 2025, with the low at 104.28% in Q4 2022.
• The 5-year median for FCF Margin is 22.1% (2026), against an average of 19.71%.
• The sharpest annual moves came in 2023 and 2026: FCF Margin jumped 6981 bps in 2023, then slumped 9594 bps in 2026.
• Ptc Therapeutics' FCF Margin stood at 104.28% in 2022, then soared by 67 bps to 34.47% in 2023, then surged by 54 bps to 15.84% in 2024, then slumped by 40 bps to 22.25% in 2025, then soared by 258 bps to 35.21% in 2026.
• Business Quant data shows PTCT's FCF Margin at 35.21% in Q2 2026, 22.1% in Q1 2026, and 22.25% in Q4 2025.